NKGen Biotech Secures $25.8M Secured Promissory Note with Highly Restrictive Terms

summarizeSummary

NKGen Biotech entered into a secured promissory note for $25.8 million, formalizing prior undocumented advances and securing a small amount of new capital under highly restrictive and costly terms.

check_boxKey Events

• Secured Promissory Note Executed

  NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. entered into a secured promissory note with AlpineBrook Capital GP I Limited for an original principal amount of $25,840,106.

• Formalizes Undocumented Advances

  The note primarily documents $25,540,106 in cash advances made by the lender since late 2024, with only an incremental $300,000 representing new capital funded contemporaneously with execution.

• High Interest and Default Rates

  The note bears interest at 12% per annum, with a default interest rate of 24% per annum if an event of default occurs.

• Extensive Collateral and Restrictive Covenants

  The borrowers granted security interests in substantially all U.S. personal property, U.S. real property, and shares of NKGen Korea. The note also includes restrictive covenants limiting additional indebtedness, liens, and equity issuances.

auto_awesomeAnalysis

This filing reveals NKGen Biotech's entry into a substantial secured promissory note, primarily to formalize $25.5 million in previously undocumented cash advances from AlpineBrook Capital. While it provides a small amount of new capital ($300,000) and extends the repayment term, the terms are extremely unfavorable, reflecting the company's distressed financial position. The note carries a high 12% interest rate (24% on default), demands extensive collateral including substantially all U.S. assets and NKGen Korea shares, and imposes restrictive covenants that severely limit future financing and operational flexibility. The "most favored nation" clause and right of first refusal on NKGen Korea shares further entrench the lender's control. This agreement highlights significant financial challenges and places the company under considerable financial burden and lender oversight.